ジェネリック医薬品の世界市場：現状分析と予測（2021年～2027年）

世界のジェネリック医薬品の市場規模は、予測期間（2021年～2027年）中に約7％のCAGRで成長すると予測されています。

ジェネリック医薬品市場の成長は、世界の疾病の蔓延、新興経済諸国における強力な飲料インフラ、医薬品に関する認知度の向上が要因と考えられます。また、壮年人口の増加、静脈注射用ジェネリック製品の発売の増加も、予測期間中の市場の成長を促進すると予想されます。

当レポートでは、世界のジェネリック医薬品市場について調査しており、市場の洞察、市場の動向、競合シナリオ、企業概要など、包括的な情報を提供しています。

目次

第1章 市場のイントロダクション

• 市場の定義
• 制限
• ステークホルダー
• レポートで使用される通貨

第2章 調査方法または仮定

• ジェネリック医薬品市場の調査プロセス
• ジェネリック医薬品市場の調査手法
• 予測方法
• 回答者のプロファイル
• ジェネリック医薬品市場調査の主な目的

第3章 市場の要約

第4章 エグゼクティブサマリー

第5章 ジェネリック医薬品市場におけるCOVID-19の影響

第6章 ジェネリック医薬品市場の収益（2019年～2027年）

第7章 市場の洞察：タイプ別

• シンプルジェネリック
• スーパージェネリック
• バイオシミラー

第8章 市場の洞察：アプリケーション別

• 神経疾患
• 心臓病
• 代謝性疾患
• 感染症
• 整形外科疾患
• 泌尿生殖器/ホルモン性疾患
• 呼吸器疾患
• その他

第9章 市場の洞察：流通チャネル別

• オフライン
• オンライン

第10章 市場の洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他の北米
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • その他のアジア太平洋
• その他

第11章 ジェネリック医薬品市場力学

• 市場促進要因
• 市場の課題
• 影響分析

第12章 ジェネリック医薬品市場の機会

第13章 ジェネリック医薬品市場の動向

第14章 法規制の枠組み

第15章 需要と供給側の分析

• 需要側分析
• 供給側分析

第16章 バリューチェーン分析

第17章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第18章 会社概要

• Cipla Ltd.
• Pfizer Inc.
• Fresenius Medical Care AG & Co. KGaA
• Aurobindo Pharma Limited
• Amneal Pharmaceuticals Inc.
• Alkem Laboratories Limited
• Teva Pharmaceutical Industries Limited
• Mylan N.V.
• Lupin Limited
• Sanofi S.A.

第19章 免責事項

The Generic Drugs market is predicted to grow at a CAGR of ~7% between 2021 and 2027. Key factors influencing the growth of the generic drugs market are the increasing prevalence of diseases around the world, strong healthcare infrastructure in developed economies, and increased awareness about different available medications around the world. The increasing prevalence of chronic and infectious diseases and the growing geriatric population in most countries coupled with rising intravenous generic product launches are further expected to drive the growth of the market during the forecast period. For instance, in July 2021, Generic Ferumoxytol, an injectable drug used to treat iron deficiency anemia (IDA), was launched in the U.S. by Sandoz. The rise in product launches of injectable generic products in developed countries is further expected to drive market growth. In addition, according to the National Health Interview Survey (NHIS) ~51.8 % of adults have a minimum of one chronic disease and 27.2 % of adults have several chronic diseases. Furthermore, according to the World Health Organization (WHO), the demand for generic medicines increased because of the prevalence of chronic diseases, propelling the generic drugs industry to new heights.

Some of the major players operating in the market include: Cipla Ltd., Pfizer Inc., Fresenius Medical Care AG & Co. KGaA, Aurobindo Pharma Limited, Amneal Pharmaceuticals Inc., Alkem Laboratories Limited, Teva Pharmaceutical Industries Limited, Mylan N.V., Lupin Limited, and Sanofi S.A.

Insights Presented in the Report

"Amongst Type, biosimilar category to witness higher incremental gain during the forecast period"

Based on type, the generic drugs market is segmented into simple generic, super generic, biosimilar, and others in 2020, biosimilar drugs had a dominating share in the market. This is mainly due to the presence of a well-established infrastructure for chemical-based drugs and the increasing prevalence of chronic diseases across the world. In addition, the increasing demand for the more targeted and patient-specific drugs along with increasing investment in generic medicines because of low cost and greater opportunities in the developing nations like India and China is further expected to drive the market.

"Amongst Application, cardiovascular diseases category held a significant share in 2020"

Based on application, the market is bifurcated into neurological diseases, cardiological diseases, metabolic diseases, infectious diseases, orthopedic diseases, genitourinary/hormonal diseases, respiratory diseases, and others. Among these, cardiovascular is expected to witness significant growth in the forecast period. This is mainly due to the rising number of patients suffering from CVDs. For instance, in the U.S., about 18 million adults aged 20 and older have coronary artery disease (CAD). Furthermore, according to American Heart Association (AHA), coronary heart diseases cause 1 in every 7 deaths in the U.S., resulting in about 366,800 deaths each year. In addition, in 2020, there were 2.2 million new cases of lung cancer reported.

"Amongst Distribution Channel, online to witness higher incremental gain during the forecast period"

Based on distribution channel, the market is bifurcated into offline and online. The online segment is expected to witness significant CAGR owing to the growing penetration of e-pharmacy platforms across the world coupled with increasing awareness regarding services offered by e-pharmacy. Furthermore, the growing focus on digitization and rising internet penetration in developing nations are some other key factors driving the market.

"APAC is expected to be the Fastest-Growing Region in Global Generic Drugs Market During 2021-2027F"

For a better understanding of the market, the report is analyzed based on different regions including North America (US, Canada, Mexico, Rest of North America); Europe (UK, Germany, France, Italy, Spain, Rest of Europe); Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific); and Rest of World. In 2020, APAC dominated the market on account of the rising research and development initiatives and the presence of a large number of pharmaceutical companies in countries such as India and China of the region. For instance, as per the India Brand Equity Foundation, India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the U.S., and 25% of all medicine in the U.K.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts

• The report presents a quick review of overall industry performance at one glance

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry

• The study comprehensively covers the market across different segments

• Deep dive regional level analysis of the industry

Customization Options:

The Generic Drugs market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stakeholders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Generic Drugs Market
• 2.2. Research Methodology of the Generic Drugs Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Generic Drugs Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GENERIC DRUGS MARKET COVID-19 IMPACT

6 GENERIC DRUGS MARKET REVENUE, 2019-2027F

7 MARKET INSIGHTS BY TYPE

• 7.1. Simple
• 7.2. Super
• 7.3. Biosimilar

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Neurological Diseases
• 8.2. Cardiological Diseases
• 8.3. Metabolic Diseases
• 8.4. Infectious Diseases
• 8.5. Orthopedic Diseases
• 8.6. Genitourinary/Hormonal Diseases
• 8.7. Respiratory Diseases
• 8.8. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Offline
• 9.2. Online

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of America
• 10.2. Europe
  • 10.2.1. U.K.
  • 10.2.2. Germany
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. India
  • 10.3.3. Japan
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of the World

11 GENERIC DRUGS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 GENERIC DRUGS MARKET OPPORTUNITIES

13 GENERIC DRUGS MARKET TRENDS

14 LEGAL & REGULATORY FRAMEWORK

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porter's Five Forces Analysis

18 COMPANY PROFILED

• 18.1. Cipla Ltd.
• 18.2. Pfizer Inc.
• 18.3. Fresenius Medical Care AG & Co. KGaA
• 18.4. Aurobindo Pharma Limited
• 18.5. Amneal Pharmaceuticals Inc.
• 18.6. Alkem Laboratories Limited
• 18.7. Teva Pharmaceutical Industries Limited
• 18.8. Mylan N.V.
• 18.9. Lupin Limited
• 18.10. Sanofi S.A.

19 DISCLAIMER